MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'enzi'. Sat, 03 Sep 2011 03:30:49 +0100 http://www.medworm.com/index.php?rid=4399826&cid=t_277082_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FTU6O6Hd_s60%2F Another day, another letter to the FDA commish from a group of bipartisan US senators over the biologics debate. The latest missive comes from health committee chair Tom Harkin, John McCain, Chuck Schumer and Sherrod Brown, who are “extremely concerned about possible misinterpretations” of the biosimilars statute “that could further delay the availability of generic biologic drugs.” They are referring to a provision in the healthcare reform law that says generics can enter the market after a brand-name biologic has had exclusivity for 12 years. But earlier this month, a different group of senators - Orrin Hatch, Kay Hagan, Michael Enzi and John Kerry - wrote FDA commish Margaret Hamburg to urge a different interpretation that would favor brand-name drugmakers and biotechs. At issue... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4399826 Tue, 25 Jan 2011 16:57:23 +0100 4399826 http://www.medworm.com/index.php?rid=4382949&cid=t_277082_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FbWRWTVXZO5M%2F Another nasty lobbying battle has broken out over biosimilars. And the latest involves a group of generic drugmakers, insurers and pharmacy benefit managers, which are pushing back against a recent effort by brand-name drugmakers to weaken a part of healthcare reform that is supposed to create competition for expensive biologics. The provision says generics can enter the market after a brand-name biologic has had exclusivity for 12 years. But earlier this month, a bipartisan group of four US Senators - including Orrin Hatch, Kay Hagan, Michael Enzi and John Kerry - wrote FDA commish Margaret Hamburg to urge a different interpretation that would favor brand-name drugmakers and biotechs. Their letter was circulated on and beyond Capitol Hill by, among others, the BIO trade group. At issue is... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4382949 Fri, 21 Jan 2011 14:25:26 +0100 4382949 http://www.medworm.com/index.php?rid=2734000&cid=t_277082_87_f&fid=38368&url=http%3A%2F%2Fwww.youtube.com%2Fv%2FsM9KcAS5_K4%26amp%3Brel%3D1%26amp%3Bcolor1%3Dd6d6d6%26amp%3Bcolor2%3Df0f0f0%26amp%3Bborder%3D0%26amp%3Bfs%3D1%26amp%3Bhl%3Den%26amp%3Bautoplay%3D0%26amp%3Bshowinfo%3D0%26amp%3Biv_load_policy%3D3%26amp%3Bshowsearch%3D0 One of my favorite movies is 1776, the musical. In July 1776, Congress was working on the Declaration of Independence. A rather controversial undertaking with far reaching implications. In July 2009, Congress was tackling another controversial undertaking with far reaching implications. I am speaking of course about health reform. The parallels, and lessons learned, are striking. Today, health reform has its Gang of Six (Senators Max Baucus, Jeff Bingaman, Kent Conrad, Charles Grassley, Michael Enzi, and Olympia Snowe). Congress in 1776 appointed a Committee of Five (John Adams, Ben Franklin, Thomas Jefferson, Robert Livingston, and Roger Sherman) to assist with the drafting of the Declaration of Independence. President Obama observed that during July and August “everybody in Washington ... Disruptive Women in Health Care blogs http://www.medworm.com/rss/comments.php?id=2734000 Wed, 26 Aug 2009 11:56:51 +0100 2734000 http://www.medworm.com/index.php?rid=2183855&cid=t_277082_87_f&fid=36438&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FCato-at-liberty%2F%7E3%2F537472340%2F Sen. Mike Enzi (R-WY), the ranking Republican on the Senate’s Health, Education, Labor, and Pensions Committee, has a good op-ed in today’s edition of The Hill. Enzi rather interestingly does not see Medicare Part D as an example of Congress “simply throwing more money at Medicare.” That aside, Enzi stakes out a position against creating a new Medicare-like program to compete with private insurance, and against price controls in health care.  Those are two of the three positions I advised free-market advocates to take in this op-ed. The third is a firm opposition to mandates that require individuals to purchase health insurance, whether directly or through an employer.  I’m sure Enzi’s saving that for his next op-ed. (Source: Cato-at-liberty) Cato-at-liberty blogs http://www.medworm.com/rss/comments.php?id=2183855 Wed, 11 Feb 2009 18:31:23 +0100 2183855